Zorifertinib (AZD3759)

Catalog No.S7971

For research use only.

Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.

Zorifertinib (AZD3759) Chemical Structure

CAS No. 1626387-80-1

Selleck's Zorifertinib (AZD3759) has been cited by 5 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Other EGFR Products

Biological Activity

Description Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.
Targets
EGFR (L858R) [1]
(Cell-free assay)
EGFR (exon 19Del) [1]
(Cell-free assay)
EGFR (WT) [1]
(Cell-free assay)
0.2 nM 0.2 nM 0.3 nM
In vitro

In H3255 (L858R) cells, AZD3759 inhibits EGFR phosphorylation with IC50 of 7.2 nM. AZD3759 demonstrates inhibitory effects on both the pEGFR pathway and cell proliferation of EGFR mutation-derived cells PC-9 and H3255 with IC50 of 7.7 nM and 7 nM, respectively, showing mo activity on cell proliferation of H838 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H3255 cells NETHfIlRem:uaX\ldoF1cW:wIHHzd4F6 NYXj[|dqPzJiaB?= M2r5N2FvfGmycn;sbYZmemG2aY\lJIFo[Wmwc4SgbJVu[W5iSEOyOVUh[2WubIOg[ZhxemW|c3nu[{BGT0[UIFy4OVhTKG23dHHueEBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFA4KM7:TR?= NFvHXYozPjNzM{K1Ni=>
PC9 cells MXnGeY5kfGmxbjDhd5NigQ>? M{\kTGlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wMUmg[IVt\XSrb36gcZV1[W62IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCSQ{mgZ4VtdHNuIFnDOVA:OC5yMEe0JO69VQ>? MkK2NlY{OTN{NUK=
H838 cells NFjqS3ZHfW6ldHnvckBie3OjeR?= Mk\oTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDIPFM5KGOnbHzzMEBKSzVyPUCuNFY1PSEQvF2= MVGyOlMyOzJ3Mh?=
In vivo AZD3759 shows good oral bioavailability in dogs, and penetrates extensively into monkey brain. In a brain metastasis PC-9 (Exon19Del) model, AZD3759 (15 mg/kg) causes significant dose-dependent antitumor efficacy. [1]

Protocol (from reference)

Kinase Assay:[1]
  • IC50 determination of compounds against EGFR enzymes:

    The inhibition potency of compounds against EGFR WT and mutant enzymes is assessed using CisBio homogenous time resolved fluorescence approach (HTRF, Cat No. 62TK0PEJ) according to manufacturer’s instruction. The final enzyme concentrations used in this assay are 0.1 nM, 0.03 nM, and 0.026 nM for EGFR wild type, L858R and Exon19Del, respectively, and 0.8 μM, 4 μM and 25 μM ATP, corresponding to the Km values of EGFR enzymes, are applied accordingly. In brief, 3 μL of ATP and 2 μM TK biotin-peptide substrate are incubated in the presence or absence of serially diluted compound at room temperature in 384-well Greiner white polystyrene assay plates. The reaction is initiated by addition of 3 μL kinase which could phosphorylate the substrate peptide, and the assay buffer contains 1 mM DTT, 5 mM MgCl2, 1 mM MnCl2, and 0.01% CHAPS. After 30 minutes incubation, the reaction is stopped by the addition of 6 μl detection reagent mix containing 250 nM Strep-XL665 and TK Ab Europium Cryptate diluted in detection buffer. The plates are incubated for 1 h before the fluorescence is then measured at 615 nm and 665 nm, respectively with excitation wavelength at 320 nm by EnVision Multilabel Reader from Perkin Elmer using standard HTRF settings. The calculated signal ratio of 665 nm/615 nm is proportional to the kinase activity. The concentration of compound producing 50% inhibition of the respective kinase (IC50) is calculated using four-parameter logistic fit.

Cell Research:[1]
  • Cell lines: PC-9 (exon 19Del), H3255 (L858R) and H838 (wt) cells
  • Concentrations: ~30 mM
  • Incubation Time: 72 h
  • Method: Cell proliferation assay is determined by MTS methods. Briefly, cells are seeded in 96-well plates (at a density to allow for logarithmic growth during the 72-hour assay) and incubated overnight at 37 °C and 5% CO2. Cells are then exposed to concentrations of compounds ranging from 30 to 0.0003 mM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer’s protocol. Absorbance is measured with a Tecan Ultra instrument. Predose measurements are made, and concentration needed to reduce the growth of treated cells to half that of untreated cells (GI50) values are determined using absorbance readings.
Animal Research:[1]
  • Animal Models: Mice bearing PC-9 (Exon19Del) tumors
  • Dosages: ~15 mg/kg
  • Administration: p.o.

Solubility (25°C)

In vitro

DMSO 91 mg/mL
(197.86 mM)
Water Insoluble
Ethanol '20 mg/mL warmed

Chemical Information

Molecular Weight 459.90
Formula

C22H23ClFN5O3

CAS No. 1626387-80-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02228369 Completed Drug: AZD3759|Drug: AZD9291 EGFR Mutation Positive Advanced Non Small Cell Lung Cancer AstraZeneca November 5 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Zorifertinib (AZD3759) | Zorifertinib (AZD3759) supplier | purchase Zorifertinib (AZD3759) | Zorifertinib (AZD3759) cost | Zorifertinib (AZD3759) manufacturer | order Zorifertinib (AZD3759) | Zorifertinib (AZD3759) distributor